People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avilar Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $2.3B | 2020 |
| Lusaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $954.8M | 2022 |
| Cortria Corp | — | Pharmaceuticals | Seed | $1.8M | $70.0M | 2009 |
Daniel Grau at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Grau on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Brian Halak | 1 | 10 |
| Stephen Reeders | 1 | 9 |
| David Neafus | 1 | 7 |
| Paulina Hill | 1 | 5 |
| Milind Deshpande | 1 | 4 |
| Richard King | 1 | 3 |
| Ramin Farzaneh-Far | 1 | 3 |
| Jay Hachigian | 1 | 3 |
| Neil Buckley | 1 | 3 |
| Martin Freed | 1 | 3 |
| CATHERINE RIESEN | 1 | 2 |
| Jerzy Gebicki | 1 | 1 |
| Edward Monaghan | 1 | 1 |
| THERESA CAMERON | 1 | 1 |
| STEPHANIE TOZZO | 1 | 1 |
| PHIL GRAHAM | 1 | 1 |
| ADAM MUZIKANT | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.